REGENXBIO Inc.
RGNX· Nasdaq
RGNXREGENXBIO Inc.
Filed Feb 28, 2023 · 10-K · 59 days after period end · 0000950170-23-005085
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 |
|---|---|---|---|---|
| Revenue | $31.35M | $398.66M | $21.45M | $11.77M |
| Net Income | -$59.94M | $294.02M | -$46.24M | -$26.46M |
| EPS Diluted | — | — | -$1.24 | -$0.72 |
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2022 · filed Feb 28, 2023 · 59 d after period end
